Virus inactivation composition

Abstract

To provide a composition for virus inactivation.SOLUTION: A composition for virus inactivation is prepared that contains (A) an acid of 0.15-1 w / v%, (B) a salt of 0.05-2 w / v%, and (C) lower alcohol of 10 w / v% or less, and has a pH of 3-5. Preferably, such a composition for virus inactivation does not contain (C) lower alcohol substantially or at all.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a virus inactivating composition, more particularly to a virus inactivating composition that has an inactivating effect on viruses and has a lower alcohol content of a specific amount or less. [Background technology]

[0002] The threat of various pathogenic viruses has a major impact on our lives. For example, the outbreak of COVID-19 virus infection is a threat to humans and is completely changing the way we live. In addition to seasonal influenza, which recurs annually, mainly in winter, new viruses can enter the human world from birds or pigs and acquire the ability to infect humans, so it can be said that we are constantly exposed to new dangers when it comes to viruses.

[0003] Viruses evolve by changing their capabilities through natural mutations and escape mutations. Virus-neutralizing antibodies have been frequently reported, and treatments exist. However, given the constantly changing nature of viruses, it is considered extremely important to prevent infection before it occurs, and there is a growing need for drugs with antiviral properties.

[0004] Currently, lower alcohols are widely used in virus inactivation compositions. For example, a disinfectant / virus inactivation composition containing a lower alcohol, a cationic surfactant, and an alkaline agent has been proposed (Patent Document 1). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Publication No. 2021-155368 Summary of the Invention [Problem to be solved by the invention]

[0006] The frequent use of products containing lower alcohols such as ethanol can cause problems such as rough skin and deterioration or changes in the properties of the object to which they are applied. For example, many sprays that are effective against viruses contain high concentrations of ethanol, and when sprayed onto an object, there is the issue that the quality of the object can be altered depending on the material it is made of.

[0007] An object of the present invention is to provide a highly safe virus inactivating composition that has little effect on the skin or objects to be treated. [Means for solving the problem]

[0008] As a result of extensive research to solve this problem, the inventors discovered that by adding specific concentrations of an acid and a salt and adjusting the pH, a virus inactivation effect can be achieved even when the concentration of a lower alcohol such as ethanol is kept low, and thus the present invention was completed.

[0009] That is, the present invention provides the following virus inactivation compositions. Section 1. A virus inactivation composition comprising (A) 0.15 to 1 w / v % of acids, (B) 0.05 to 2 w / v % of salts, and (C) a lower alcohol content of 10 w / v % or less and a pH of 3 to 5. Section 2. Item 1. The virus inactivating composition according to Item 1, wherein the component (A) is one or more acids selected from the group consisting of citric acid, malic acid, gluconic acid, lactic acid, phosphoric acid, sorbic acid, and phytic acid. Section 3. Item 3. The virus inactivation composition according to Item 1 or 2, wherein the component (B) is one or more selected from the group consisting of sodium citrate, potassium citrate, sodium gluconate, sodium malate, sodium tartrate, sodium lactate, and trisodium phosphate. Section 4. Item 4. The virus inactivating composition according to any one of Items 1 to 3, which does not contain the component (C). Section 5. Item 5. The virus inactivating composition according to any one of Items 1 to 4, wherein the virus is an enveloped RNA virus.

[0010] Furthermore, the present invention provides the following methods. Section 6. A method for imparting to a composition containing (A) 0.15 to 1 w / v% of acids and (B) 0.05 to 2 w / v% of salts an inhibitory effect on rough or deteriorated skin of a target by adjusting the content of (C) a lower alcohol to 10 w / v% or less and the pH to 3 to 5. [Effects of the Invention]

[0011] The present invention can provide a highly safe virus inactivating composition that has little effect on the skin or objects to be treated. DETAILED DESCRIPTION OF THE INVENTION

[0012] In this specification, the content unit "w / v%" is synonymous with "g / 100 ml."

[0013] [Virus inactivation composition] The virus inactivating composition of the present invention contains (A) 0.15 to 1 w / v % of acids, (B) 0.05 to 2 w / v % of salts, (C) a lower alcohol content of 10 w / v % or less, and a pH of 3 to 5.

[0014] ((A) Acids) The virus inactivating composition of the present invention contains (A) an acid. The acid is preferably either an organic acid or an inorganic acid, and examples thereof include hydroxy acids such as citric acid, malic acid, gluconic acid, and lactic acid, and other acids such as phosphoric acid, sorbic acid, and phytic acid. These acids may be used alone or in combination of two or more. Of these, one or more acids selected from the group consisting of citric acid, malic acid, gluconic acid, and phosphoric acid are particularly preferred.

[0015] From the viewpoint of exerting the effects of the present invention, the content of acids relative to the total amount of the virus inactivating composition of the present invention is preferably 0.15 w / v% or more and 1 w / v% or less, more preferably 0.2 w / v% or more and 0.8 w / v% or less, and even more preferably 0.4 w / v% or more and 0.8 w / v% or less.

[0016] ((B) Salts) The virus inactivating composition of the present invention contains salts. Salts are preferably salts of organic acids or inorganic acids, and examples thereof include sodium salts, potassium salts, magnesium salts, calcium salts, and ammonium salts. As salts, sodium salts and potassium salts are preferred, and sodium salts are more preferred.

[0017] For example, in the present invention, salts include, but are not limited to, sodium citrate, potassium citrate, sodium malate, sodium gluconate, potassium gluconate, sodium succinate, sodium tartrate, trisodium phosphate, sodium lactate, etc. These may be used alone or in combination of two or more. Of these, one or more selected from the group consisting of sodium citrate, potassium citrate, sodium gluconate, sodium malate, sodium tartrate, sodium lactate, and trisodium phosphate are particularly preferred. Although not limited thereto, salts of the same acid as the acid of component (A) are also preferred.

[0018] From the viewpoint of exerting the effects of the present invention, the content of salts relative to the total amount of the virus inactivating composition of the present invention is preferably 0.05 w / v% or more and 2 w / v% or less, more preferably 0.1 w / v% or more and 1.5 w / v% or less, and even more preferably 0.5 w / v% or more and 1.2 w / v% or less.

[0019] In the virus inactivating composition of the present invention, the ratio of salts to acids is preferably 0.3 to 3 parts by mass, more preferably 0.5 to 2 parts by mass, and even more preferably 1 to 1.5 parts by mass, per 1 part by mass of acids.

[0020] (lower alcohol) As used herein, the term "lower alcohol" refers to C1-3 alcohols, specifically methanol, ethanol, isopropyl alcohol, and propanol.

[0021] In the virus inactivating composition of the present invention, the content of the lower alcohol relative to the total amount of the virus inactivating composition is 10 w / v% or less, preferably less than 10 w / v%, more preferably 5 w / v% or less, and even more preferably 1 w / v% or less. It is particularly preferred that the virus inactivating composition of the present invention is substantially free of or completely free of lower alcohol. Here, "substantially free" refers to a content of the lower alcohol relative to the total amount of the virus inactivating composition of, for example, 0.1 w / v% or less, preferably 0.01 w / v% or less.

[0022] In the virus inactivating composition of the present invention, the ethanol content relative to the total amount of the virus inactivating composition can be 10 w / v% or less, preferably less than 10 w / v%, more preferably 5 w / v% or less, and even more preferably 1 w / v% or less. It is particularly preferred that the virus inactivating composition of the present invention is substantially free of ethanol or completely free of ethanol. Here, "substantially free" refers to a content of ethanol relative to the total amount of the virus inactivating composition of, for example, 0.1 w / v% or less, preferably 0.01 w / v% or less.

[0023] From the viewpoint of exerting the effects of the present invention, the content of the lower alcohol relative to the total amount of the virus inactivating composition of the present invention may be, for example, 0.01 w / v% or more and 10 w / v% or less, 0.01 w / v% or more and 10 w / v% or less, or 0.0 w / v% or more and 5 w / v% or less.

[0024] (water) The virus inactivating composition of the present invention can be blended with water, such as purified water such as ion-exchanged water, ordinary tap water, or industrial water. The content of water relative to the total amount of the virus inactivating composition is preferably 80 w / v % or more, more preferably 90 w / v % or more, even more preferably 95 w / v % or more, and even more preferably 97 w / v % or more.

[0025] (Polyhydric alcohol) The virus inactivating composition of the present invention can contain a polyhydric alcohol instead of or together with water. Examples of such polyhydric alcohols include ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, butylene glycol, propanediol, glycerin, and trimethylolpropane. The content of the polyhydric alcohol relative to the total amount of the virus inactivating composition can be 80 w / v % or more, 90 w / v % or more, or even 95 w / v % or more.

[0026] (virus) The virus referred to in this specification includes, but is not limited to, the non-enveloped virus that does not have an envelope and is resistant to alcohol, and the virus that has an envelope.Preferably, the virus that has an envelope is the target, and among them, the RNA virus such as Coronaviridae, Orthomyxoviridae, Flaviviridae, Togaviridae, Paramyxoviridae, Rhabdoviridae, Bunyaviridae or Filoviridae, or the DNA virus such as Herpesviridae, Poxviridae or Hepadnaviridae is more preferred, the RNA virus that has an envelope is more preferred, and the virus of Orthomyxoviridae is even more preferred.

[0027] (pH) From the standpoint of component stability and safety, the virus inactivating composition of the present invention preferably has a pH of 3 to 5. More preferably, the virus inactivating composition has a pH of 3 to 4.5. The pH of the virus inactivating composition can be measured at 20°C using a commercially available pH meter (for example, Model F-52 (registered trademark) manufactured by Horiba, Ltd.).

[0028] (viscosity) From the viewpoint of component stability, etc., the viscosity of the virus inactivating composition of the present invention at 25°C, with SPINDLE No. M1 and at 100 rpm is preferably about 0.5 to 1000 mPa·s, and more preferably about 3 to 100 mPa·s. The viscosity of the virus inactivating composition can be measured at 25°C using a commercially available viscometer (for example, Model TVB-10M, manufactured by Toki Sangyo Co., Ltd.).

[0029] (Other ingredients) In addition to (A) acids, (B) salts, and (C) lower alcohols, the virus inactivating composition of the present invention may contain optional components as appropriate, as long as the optional components do not impair the effects of the present invention. Examples of optional components include surfactants, chelating agents, polymers, preservatives, natural product extracts, dispersants, antioxidants, thickeners, viscosity reducers, stabilizers, deodorizers, fragrances, and colorants.

[0030] The virus inactivating composition of the present invention is also preferably a composition that does not contain or substantially does not contain chlorine oxides (chlorine, hypochlorous acid, chlorous acid, chlorine dioxide, etc.).

[0031] Here, "substantially free" means that the content of the component in question is, for example, 0.1 w / v % or less, preferably 0.01 w / v % or less.

[0032] (Applications, etc.) The virus inactivating composition of the present invention can be applied directly to, but is not limited to, skin or objects where changes in properties are undesirable, particularly to the skin of fingers, arms, etc.; tableware, countertops, cooking utensils, etc.; toilet areas such as toilet seats, toilet bowls, toilet lids, flush levers, doorknobs, electric switches, and handrails; or tables, chairs, medical equipment, mobile phones, smartphones, tablet PCs, and computer peripherals such as mice and keyboards.

[0033] The virus inactivating composition of the present invention is provided in a form that can be brought into contact with an object by coating, immersion, spraying, etc. The virus inactivating composition of the present invention can preferably be brought into contact with an object by spraying.

[0034] The virus inactivating composition of the present invention can be provided in the form of, but is not limited to, an aerosol, a spray, or a sheet impregnated into fibers, nonwoven fabric, etc. In the case of an aerosol or spray, the virus inactivating composition of the present invention can be preferably contained in a container such as a trigger spray or dispenser for use. When provided in the form of a sheet impregnated into nonwoven fabric, etc., preferred examples of the material for the sheet include recycled fibers, synthetic fibers, plant fibers, nonwoven fabrics, woven fabrics, and mesh fabrics.

[0035] The virus inactivating composition of the present invention can be used 1 to 20 times a day, preferably about 2 to 15 times a day, and more preferably about 5 to 10 times a day. In view of the properties of the virus inactivating composition of the present invention, it can also be used as frequently as 5 to 15 times a day.

[0036] In terms of antiviral effect, the amount of the virus inactivating composition of the present invention used per administration is preferably about 0.2 to 3 ml, and more preferably about 0.5 to 2 ml.

[0037] [Method for preventing rough or deteriorated skin] The present invention also relates to a method for imparting to a composition containing 0.15 to 1 w / v % of (A) acids and 0.05 to 2 w / v % of (B) salts an effect of inhibiting rough skin or deterioration of a target object by adjusting the content of (C) a lower alcohol to 10 w / v % or less and the pH to 3 to 5. In the deterioration inhibition method of the present invention, the (A) acids, (B) salts, (C) lower alcohol, pH, and other conditions are the same as those described for the virus inactivating composition. [Example]

[0038] Next, the present invention will be described in detail with reference to examples, but the present invention is not limited to the following examples. The unit of the amount of each component in the tables is w / v % unless otherwise specified in the tables.

[0039] [1] Virus inactivation effect evaluation test The compositions of the Examples and Comparative Examples shown in Table 1 were prepared by conventional methods, and the virus inactivation effects of these compositions were evaluated.

[0040] The viral inactivation effect was evaluated as follows.

[0041] (Target virus) Influenza virus A(H1N1) (A / PR / 8 / 1934; ATCC VR-1469)

[0042] (Cells used) MDCK cells

[0043] (Culture medium) E-MEM medium was used after adding fetal bovine serum (FBS).

[0044] (Preparation of virus solution) The virus was added to cells prepared in advance, and after culturing for a certain period of time, the culture medium was subjected to a freeze-thaw treatment, and the supernatant obtained by centrifugation was used as the virus solution.

[0045] (Experimental Method) 0.1 mL of the virus solution was added to 0.9 mL of the solution of the Examples and Comparative Examples shown in Table 1, and the reaction was stopped after 30 seconds, followed by serial dilution. 0.1 mL of this diluted solution was placed in a plate on which cells had been cultured in advance, and cultured for 3 to 4 days under conditions of 37°C and 5% CO2. After culture, cytopathic effect was confirmed by microscopic observation, and the 50% tissue culture infectious dose of virus (TCID 50 : Cultured cells are infected with a virus, and the amount of virus that infects 50% of the cells is called TCID 50 The viral infectivity (TCID 50 / mL).

[0046] Viral infectivity before action (TCID 50 / mL) (logTCID 50 / mL) and the viral infectivity after the treatment (TCID 50 / mL) (logTCID 50 The difference between the values of the virus infectivity titers (mg / mL) was calculated and used as the reduction in the virus infectivity titer. A reduction in the virus infectivity titer of 4.0 or more was evaluated as ⊚, a reduction in the virus infectivity titer of 2.0 or more but less than 4.0 was evaluated as ◯, and a reduction in the virus infectivity titer of less than 2.0 was evaluated as x. Of these, ⊚ and ◯ were judged as good, and x was judged as poor.

[0047] The results are shown in Table 1. [Table 1]

[0048] As a result of the evaluation test, the compositions of the examples showed a higher virus inactivation effect than the compositions of the comparative examples.

[0049] [2] Impact assessment test on the target object The compositions of the examples and comparative examples shown in Table 2 were prepared by conventional methods, and about 0.5 ml of each composition was sprayed onto an object, and without wiping it off, the changes were checked immediately. The evaluation criteria are shown in Table 3. Evaluation was carried out according to the following evaluation criteria. A comprehensive judgment was made, and those that were all ◯ were given an overall evaluation of ◯, which was considered good.

[0050] [Table 2]

[0051] [Table 3]

[0052] The results of the evaluation test showed that the compositions of the examples had no effect on the objects and maintained the objects in good condition, compared to the compositions of the comparative examples.

[0053] [3] Skin irritation evaluation test 0.5 mL of each composition from the Examples and Comparative Examples was applied to the forearm five times at one-hour intervals, and then (1) irritation and (2) dryness (chapping) of the skin were evaluated using a sensory evaluation scale of 1 to 3. The test was conducted by five people, and the average score was calculated. The evaluation criteria are shown below.

[0054] <Evaluation items and criteria> (1) Irritation (burning sensation, pain, itching, etc.) No feeling = 3 points, Some feeling = 2 points, Feeling = 1 point (2) Dry (rough) skin No feeling = 3 points, Some feeling = 2 points, Feeling = 1 point

[0055] ◎: Average score is 2.5 or higher ○: Average store is 2.0 or more, less than 2.5 ×: Average score is less than 2.0 For both (1) irritation and (2) dryness (chapping) of the skin, products rated as good were rated as 0 or above.

[0056] The results are shown in Table 4 below. [Table 4]

[0057] The results of the evaluation test showed that the compositions of the examples were less likely to cause skin irritation or dryness compared to the compositions of the comparative examples.

Claims

1. A virus inactivation composition comprising: (A) 0.15 to 1 w / v % of one or more selected from the group consisting of citric acid, malic acid, and phosphoric acid; (B) 0.05 to 2 w / v % of one or more selected from the group consisting of sodium citrate, potassium citrate, sodium malate, and trisodium phosphate; and (C) a lower alcohol content of 10 w / v % or less and a pH of 3 to 5.

2. 2. The virus inactivating composition according to claim 1, which does not contain component (C).

3. 3. The virus inactivating composition according to claim 1, wherein the virus is an enveloped RNA virus.

4. A method for imparting to a composition an inhibitory effect on rough or deteriorated skin of a subject to be applied, the composition comprising (A) 0.15 to 1 w / v % of one or more selected from the group consisting of citric acid, malic acid, and phosphoric acid, and (B) 0.05 to 2 w / v % of one or more selected from the group consisting of sodium citrate, potassium citrate, sodium malate, and trisodium phosphate, and (C) a lower alcohol content of 10 w / v % or less and a pH of 3 to 5.

Images